Drug evaluation: CP-751871, a human antibody against type I insulin-like growth factor receptor for the potential treatment of cancer

Curr Opin Mol Ther. 2007 Jun;9(3):299-304.


Several phase II trials of CP-751871 are currently underway, including a phase Ib/II [corrected] trial of CP-751871 in combination with paclitaxel and carboplatin in patients with advanced NSCLC, a phase II trial of CP-751871 in combination with docetaxel and prednisone in patients with hormone-refractory prostate cancer, and a phase II trial of CP-751871 in combination with exemestane in hormone receptor positive advanced breast cancer [corrected]

MeSH terms

  • Antibodies / adverse effects
  • Antibodies / immunology
  • Antibodies / therapeutic use*
  • Carboplatin / therapeutic use
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Drug Evaluation, Preclinical
  • Humans
  • Neoplasms / drug therapy*
  • Paclitaxel / therapeutic use
  • Receptors, Somatomedin / immunology*


  • Antibodies
  • Receptors, Somatomedin
  • Carboplatin
  • Paclitaxel